Previous 10 | Next 10 |
Vericel press release (NASDAQ:VCEL): Q1 GAAP EPS of -$0.15 misses by $0.03. Revenue of $36.07M (+4.3% Y/Y) beats by $1.76M. The company reaffirmed financial guidance for FY2022: Total net revenue in the range of $178M to $189M vs. consensus of $183.62M; MACI revenue expected to be in the...
First Quarter Total Net Revenue of $36.1 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today re...
Vericel (NASDAQ:VCEL) is scheduled to announce Q1 earnings results on Wednesday, May 4th, before market open. The consensus EPS Estimate is -$0.12 (-71.4% Y/Y) and the consensus Revenue Estimate is $34.31M (-0.8% Y/Y). Over the last 2 years, VCEL has beaten EPS estimates 75% of the time and h...
CAMBRIDGE, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its first-quarter 2022 financial results and busi...
The NexoBrid complete response letter sparked a market overreaction on Vericel Corporation stocks. Coupled with the 2021/2022 Biotech Bear market, Vericel shares are trading at a deep bargain to their intrinsic value. Maci continues to generate increasing revenue year-over-year. T...
Vericel is a high growth, disruptive medical technology company with average 5-year sales growth of 24%. The Company’s tissue repair and restoration products are proprietary and backed by medical research showing greater effectiveness than traditional competing solutions/approa...
CAMBRIDGE, Mass., March 15, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present at the Canaccord Genuity Musculoskeletal Conferen...
CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will participate in a fireside chat at the Cowen 42 nd Ann...
Image source: The Motley Fool. Vericel (NASDAQ: VCEL) Q4 2021 Earnings Call Feb 24, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: Vericel (VCEL) Q4 2021 Earnings Call Transcript
CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Board of Directors has appointed Jonathan Siegal as the Company’s Principal Accounting ...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Karen Mahoney as Chief Human Resources Officer following the retirement of Heidi Hassen, w...
CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its second-quarter 2024 financial results on Thursday, August 1, 2024. Vericel’s m...
2024-07-08 00:00:04 ET Ryan Zimmerman from BTIG issued a price target of $56.00 for VCEL on 2024-07-05 10:09:00. The adjusted price target was set to $56.00. At the time of the announcement, VCEL was trading at $46.68. The overall price target consensus is at $48.00 with...